These results strongly provide a rationale for considering the use of p110δ-selective inhibitors in breast cancer treatment and for the establishment of p110δ expression as a useful prognostic marker for the response of tumours expressing WT PTEN to p110δ inhibitors. The gene discussed is PIK3CD; the disease is neoplasm.